First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.

ABSTRACT:

Objective

To compare WHO first-line antiretroviral therapy (ART) with nonnucleoside reverse transcriptase inhibitors (NNRTI)-based regimen with a boosted protease inhibitor (bPI) regimen in a resource-limited setting regarding treatment outcome and emergence of drug resistance mutations (DRMs).

Methods

Treatment-naive adults were randomized to nevirapine (NVP) or ritonavir-boosted lopinavir (LPV/r) regimens each in combination with tenofovir (TDF)/emtricitabine (FTC) or zidovudine (ZDV)/lamivudine (3TC). Primary endpoint was the incidence of therapeutical (clinical and/or virologic) failure at week 48 with follow-up till week 96.

Results

Four hundred and twenty-five patients (120 men; 305 women) received at least one dose of the study drug. mITT analysis showed no dif

SUBMITTER: Clumeck N 

PROVIDER: S-EPMC4004638 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature